US 11,052,077 B2
Methods of treating lung cancer
Sundar Srinivasan, Corona Del Mar, CA (US); and Christina Chow, Seattle, WA (US)
Assigned to BOW RIVER LLC, Corona Del Mar, CA (US)
Filed by Bow River LLC, Corona Del Mar, CA (US)
Filed on Jan. 15, 2021, as Appl. No. 17/150,467.
Application 17/150,467 is a continuation of application No. 17/082,902, filed on Oct. 28, 2020.
Application 17/082,902 is a continuation of application No. 16/408,931, filed on May 10, 2019, granted, now 10,857,144, issued on Dec. 8, 2020.
Application 16/408,931 is a continuation in part of application No. 15/596,585, filed on May 16, 2017, granted, now 10,376,507, issued on Aug. 13, 2019.
Prior Publication US 2021/0154181 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61K 31/4468 (2006.01); A61K 9/20 (2006.01); A61K 31/4745 (2006.01); A61K 9/00 (2006.01); A61P 25/18 (2006.01); A61K 31/5383 (2006.01); A61K 31/519 (2006.01); A61P 35/04 (2006.01); A61P 25/16 (2006.01); A61K 31/454 (2006.01); A61K 31/397 (2006.01); A61K 31/00 (2006.01); A61K 9/08 (2006.01); A61K 9/10 (2006.01); A61K 9/48 (2006.01); A61K 31/498 (2006.01); A61K 31/407 (2006.01); A61K 31/506 (2006.01); A61P 35/02 (2006.01); A61K 31/497 (2006.01); A61K 31/4995 (2006.01); A61K 31/5395 (2006.01)
CPC A61K 31/4468 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/0078 (2013.01); A61K 9/0095 (2013.01); A61K 9/08 (2013.01); A61K 9/10 (2013.01); A61K 9/2004 (2013.01); A61K 9/4841 (2013.01); A61K 31/00 (2013.01); A61K 31/397 (2013.01); A61K 31/407 (2013.01); A61K 31/454 (2013.01); A61K 31/4745 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4995 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5383 (2013.01); A61K 31/5395 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 35/02 (2018.01); A61P 35/04 (2018.01)] 20 Claims
 
1. A method of treating lung cancer in a patient in need thereof with an antineoplastic drug which is a CYP3A4 substrate, wherein the patient is treated with posaconazole, comprising:
(a) stopping posaconazole treatment;
(b) delaying administering, for at least 9 days after stopping posaconazole treatment, a dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition of the patient had not been treated with posaconazole; and then
(c) administering the anti-neoplastic drug.